FAQ: Kairos Pharma's KOL Event on Phase 2 ENV105 Prostate Cancer Trial

What is the main topic of this announcement?

The announcement covers Kairos Pharma Ltd.’s upcoming key opinion leader event to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer, focusing on safety and efficacy findings from the ENV105 and apalutamide combination therapy.

When and where is the KOL event taking place?

The key opinion leader event will be hosted on September 18, 2025, at 5 p.m. ET. The specific location is not mentioned in the content, but it is organized by Kairos Pharma Ltd., which is based in Los Angeles, California.

Who is involved in this event and the trial?

Kairos Pharma Ltd. (NYSE American: KAPA) is hosting the event, with CEO Dr. John Yu leading the discussion. Key opinion leaders will provide expert perspectives on the Phase 2 trial of ENV105, which targets advanced prostate cancer patients.

Why is this event and the ENV105 trial significant?

This event is significant because it highlights ENV105’s potential to address cancer drug resistance by targeting CD105, a protein that drives resistance to standard therapies. The interim efficacy results could underscore its role in restoring the effectiveness of treatments for prostate cancer and other cancers.

How does ENV105 work in treating cancer?

ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.

What are the current stages of development for ENV105?

ENV105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials aim to address significant unmet medical needs in oncology by overcoming drug resistance and immune suppression.

Where can I find more information about Kairos Pharma and this announcement?

For more details, you can view the full press release at https://ibn.fm/DrvAm or visit the company’s newsroom at https://ibn.fm/KAPA for the latest updates relating to KAPA.

What implications does this have for cancer treatment?

The implications include potentially overcoming drug resistance in cancer therapies, which is a major challenge in oncology. If successful, ENV105 could restore the effectiveness of standard treatments and improve outcomes for patients with advanced prostate cancer and other types of cancer.